The youngest (and as of now twitterless) Jayewickreme sibling's first publication, and a first author publication at that. Congrats to her and the entire team! @tianyangmao@maria_tokuyama@VirusesImmunity
Our latest work on endogenous retrovirus-mediated protection against vaginal HSV-2 disease is now published! Co-first authors Radeesha Jayewickreme and @tianyangmao. A quick 🧵on our findings:
https://t.co/DsUSIBmLOk
Very excited for tomorrow’s ‘aging’ themed journal club!
Traditional figure walkthrough followed by Q&A😁— we’ll be going through @corina_amor_MD’s paper titled “Senolytic CAR T cells reverse senescence-associated pathologies”
Link to paper & event via @dnatieclub ⬇️
Very insightful talk by @AlexandraBause from @ApolloHealthVC for @NucleateHQ Venture Creation Seminar Series. Especially interesting was the case study on @SamsaraTx! Register here for more: https://t.co/I5FMJESJPR
A good review of funding models in the life sciences. Tl;dr Most mechanisms depend on the success of a tiny subset to capitalize everyone else. Also, impossible to know the successful ones with any certainty beforehand.
https://t.co/ZZFcGKkmFn
The default answer for many life science PhDs is Biotech. Addressing drug affordability by changing the entire incentive structure for biotech investing will have drastic consequences.
With PhD and MD/PhD admissions season kicking into gear, I have deeply mixed feelings about recruiting the next generation of trainees into the biosciences. Many do not realize that the biotech industry is in grave danger with vast swathes of research jobs in jeopardy.